Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $22 to $20.
Cantor Fitzgerald analyst Ross Osborn reiterates SI-BONE (NASDAQ:SIBN) with a Overweight and maintains $25 price target.
SI-BONE (NASDAQ:SIBN) raises FY2025 sales outlook from $193.500 million-$197.500 million to $195.000 million-$198.000 million v...
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 24...
Truist Securities analyst Samuel Brodovsky maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $20 t...
Cantor Fitzgerald analyst Ross Osborn reiterates SI-BONE (NASDAQ:SIBN) with a Overweight and maintains $25 price target.
Needham analyst David Saxon reiterates SI-BONE (NASDAQ:SIBN) with a Buy and maintains $24 price target.
